SIBN vs. OFIX, SRDX, CRY, ANIK, XENT, UFPT, LMAT, ATEC, ATRC, and MDXG
Should you be buying SI-BONE stock or one of its competitors? The main competitors of SI-BONE include Orthofix Medical (OFIX), Surmodics (SRDX), CryoLife (CRY), Anika Therapeutics (ANIK), Intersect ENT (XENT), UFP Technologies (UFPT), LeMaitre Vascular (LMAT), Alphatec (ATEC), AtriCure (ATRC), and MiMedx Group (MDXG).
SI-BONE (NASDAQ:SIBN) and Orthofix Medical (NASDAQ:OFIX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and analyst recommendations.
Orthofix Medical received 251 more outperform votes than SI-BONE when rated by MarketBeat users. However, 67.23% of users gave SI-BONE an outperform vote while only 61.80% of users gave Orthofix Medical an outperform vote.
In the previous week, SI-BONE and SI-BONE both had 3 articles in the media. Orthofix Medical's average media sentiment score of 0.42 beat SI-BONE's score of -0.33 indicating that Orthofix Medical is being referred to more favorably in the news media.
SI-BONE has higher earnings, but lower revenue than Orthofix Medical. SI-BONE is trading at a lower price-to-earnings ratio than Orthofix Medical, indicating that it is currently the more affordable of the two stocks.
SI-BONE has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Orthofix Medical has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500.
SI-BONE currently has a consensus target price of $27.29, suggesting a potential upside of 111.03%. Orthofix Medical has a consensus target price of $18.00, suggesting a potential upside of 36.99%. Given SI-BONE's stronger consensus rating and higher probable upside, equities research analysts plainly believe SI-BONE is more favorable than Orthofix Medical.
Orthofix Medical has a net margin of -16.64% compared to SI-BONE's net margin of -29.93%. Orthofix Medical's return on equity of -14.24% beat SI-BONE's return on equity.
98.1% of SI-BONE shares are owned by institutional investors. Comparatively, 89.8% of Orthofix Medical shares are owned by institutional investors. 5.4% of SI-BONE shares are owned by company insiders. Comparatively, 4.7% of Orthofix Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
SI-BONE beats Orthofix Medical on 10 of the 17 factors compared between the two stocks.
Get SI-BONE News Delivered to You Automatically
Sign up to receive the latest news and ratings for SIBN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SIBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
